Sophia Xu
Director - Bioanalysis Daiichi Sankyo
Dr. Xiaohui (Sophia) Xu is Director of Clinical Bioanalysis at Daiichi Sankyo, Inc., where she leads bioanalytical support for global drug development programs spanning small molecules, monoclonal antibodies, and emerging therapeutic modalities. Prior to joining Daiichi Sankyo, she held positions of increasing responsibility in bioanalytical sciences at Merck and Bristol Myers Squibb. Dr. Xu is an active contributor to the scientific community through the American Association of Pharmaceutical Scientists (AAPS), several AAPS working groups, and multiple IQ Consortium initiatives. She has authored numerous peer-reviewed publications, contributed two book chapters, and served as co-editor of a scientific book.
Seminars
With more and more ADCs entering the clinic, it has never been more important to optimize clinical characterization and development strategies to demonstrate differentiation and benefit oncology patients.
Attend this session to dive into ADC clinical development strategy from bioanalytical characterization to support clinical dosing, understanding mechanisms of ADC resistance, and contextualizing opportunities to maximize differentiation in crowded oncology indications.
Workshop Highlights Include:
- Laying out ADC bioanalytical characterization to support clinical pharmacology, dosing strategy and trial design in early ADC clinical development
- Contextualizing ADC clinical development in an increasingly busy oncology therapeutic landscape: What are the strategies to deliver clinical impact with the bar for success raised?
- Breaking down tumor target expression and ADC resistance mechanisms to optimize approaches to unlock clinical benefit across combination and sequencing approaches
